Evaluation of pentisomide on stable ventricular premature beats. Comparison with placebo

S. G. Mangini, F. Mastropasqua, V. Oldani, F. Massari, G. N. Mainio, A. Ricci, D. Scrutinio, P. Rizzon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pentisomide, a new class I anti-arrhythmic drug, was compared to placebo in 50 hospitalized patients with frequent (>30 h-1) and stable ventricular premature beats (VPB) (variation less than 50% between two preliminary and one placebo 24-h Holter recordings). All patients underwent a single-dose acute oral testing followed by a short-term testing with 300 mg t.i.d. for 4 days and then by a 4-day placebo period. For the studied population, a 56.4% reduction of simple VPB and a 98.8% decrease of couplets and runs were the minimum required to define the drug efficacy and to exclude spontaneous variability, using the linear regression analysis. Pentisomide was found effective in 27 (54%) of the 50 patients after the acute test and in 23 (46%) after the short-term test. The drug induced a mild increase of PR and QRS intervals, while QTc, heart rate, blood pressure and ejection fraction showed no significant variations. Subjective tolerability was excellent.

Original languageEnglish
Pages (from-to)712-719
Number of pages8
JournalEuropean Heart Journal
Volume12
Issue number6
Publication statusPublished - 1991

Fingerprint

Ventricular Premature Complexes
Placebos
Pharmaceutical Preparations
Anti-Arrhythmia Agents
Linear Models
Heart Rate
Regression Analysis
Blood Pressure
Population
propisomide

Keywords

  • Acute test
  • Pentisomide
  • Short-term test
  • Spontaneous variability
  • Ventricular premature beats

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mangini, S. G., Mastropasqua, F., Oldani, V., Massari, F., Mainio, G. N., Ricci, A., ... Rizzon, P. (1991). Evaluation of pentisomide on stable ventricular premature beats. Comparison with placebo. European Heart Journal, 12(6), 712-719.

Evaluation of pentisomide on stable ventricular premature beats. Comparison with placebo. / Mangini, S. G.; Mastropasqua, F.; Oldani, V.; Massari, F.; Mainio, G. N.; Ricci, A.; Scrutinio, D.; Rizzon, P.

In: European Heart Journal, Vol. 12, No. 6, 1991, p. 712-719.

Research output: Contribution to journalArticle

Mangini, SG, Mastropasqua, F, Oldani, V, Massari, F, Mainio, GN, Ricci, A, Scrutinio, D & Rizzon, P 1991, 'Evaluation of pentisomide on stable ventricular premature beats. Comparison with placebo', European Heart Journal, vol. 12, no. 6, pp. 712-719.
Mangini, S. G. ; Mastropasqua, F. ; Oldani, V. ; Massari, F. ; Mainio, G. N. ; Ricci, A. ; Scrutinio, D. ; Rizzon, P. / Evaluation of pentisomide on stable ventricular premature beats. Comparison with placebo. In: European Heart Journal. 1991 ; Vol. 12, No. 6. pp. 712-719.
@article{070a3dda2d914fdb9d213616ecc97ed2,
title = "Evaluation of pentisomide on stable ventricular premature beats. Comparison with placebo",
abstract = "Pentisomide, a new class I anti-arrhythmic drug, was compared to placebo in 50 hospitalized patients with frequent (>30 h-1) and stable ventricular premature beats (VPB) (variation less than 50{\%} between two preliminary and one placebo 24-h Holter recordings). All patients underwent a single-dose acute oral testing followed by a short-term testing with 300 mg t.i.d. for 4 days and then by a 4-day placebo period. For the studied population, a 56.4{\%} reduction of simple VPB and a 98.8{\%} decrease of couplets and runs were the minimum required to define the drug efficacy and to exclude spontaneous variability, using the linear regression analysis. Pentisomide was found effective in 27 (54{\%}) of the 50 patients after the acute test and in 23 (46{\%}) after the short-term test. The drug induced a mild increase of PR and QRS intervals, while QTc, heart rate, blood pressure and ejection fraction showed no significant variations. Subjective tolerability was excellent.",
keywords = "Acute test, Pentisomide, Short-term test, Spontaneous variability, Ventricular premature beats",
author = "Mangini, {S. G.} and F. Mastropasqua and V. Oldani and F. Massari and Mainio, {G. N.} and A. Ricci and D. Scrutinio and P. Rizzon",
year = "1991",
language = "English",
volume = "12",
pages = "712--719",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Evaluation of pentisomide on stable ventricular premature beats. Comparison with placebo

AU - Mangini, S. G.

AU - Mastropasqua, F.

AU - Oldani, V.

AU - Massari, F.

AU - Mainio, G. N.

AU - Ricci, A.

AU - Scrutinio, D.

AU - Rizzon, P.

PY - 1991

Y1 - 1991

N2 - Pentisomide, a new class I anti-arrhythmic drug, was compared to placebo in 50 hospitalized patients with frequent (>30 h-1) and stable ventricular premature beats (VPB) (variation less than 50% between two preliminary and one placebo 24-h Holter recordings). All patients underwent a single-dose acute oral testing followed by a short-term testing with 300 mg t.i.d. for 4 days and then by a 4-day placebo period. For the studied population, a 56.4% reduction of simple VPB and a 98.8% decrease of couplets and runs were the minimum required to define the drug efficacy and to exclude spontaneous variability, using the linear regression analysis. Pentisomide was found effective in 27 (54%) of the 50 patients after the acute test and in 23 (46%) after the short-term test. The drug induced a mild increase of PR and QRS intervals, while QTc, heart rate, blood pressure and ejection fraction showed no significant variations. Subjective tolerability was excellent.

AB - Pentisomide, a new class I anti-arrhythmic drug, was compared to placebo in 50 hospitalized patients with frequent (>30 h-1) and stable ventricular premature beats (VPB) (variation less than 50% between two preliminary and one placebo 24-h Holter recordings). All patients underwent a single-dose acute oral testing followed by a short-term testing with 300 mg t.i.d. for 4 days and then by a 4-day placebo period. For the studied population, a 56.4% reduction of simple VPB and a 98.8% decrease of couplets and runs were the minimum required to define the drug efficacy and to exclude spontaneous variability, using the linear regression analysis. Pentisomide was found effective in 27 (54%) of the 50 patients after the acute test and in 23 (46%) after the short-term test. The drug induced a mild increase of PR and QRS intervals, while QTc, heart rate, blood pressure and ejection fraction showed no significant variations. Subjective tolerability was excellent.

KW - Acute test

KW - Pentisomide

KW - Short-term test

KW - Spontaneous variability

KW - Ventricular premature beats

UR - http://www.scopus.com/inward/record.url?scp=0025797806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025797806&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 712

EP - 719

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 6

ER -